sumatriptan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives	2543	103628-46-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: GR43175 GR 43175 sumatriptan sumatriptan succinate	A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS. Molecular weight: 295.40 Formula: C14H21N3O2S CLOGP: 0.74 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 65.20 ALOGS: -3.37 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

GR43175
GR 43175
sumatriptan
sumatriptan succinate

A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.

Molecular weight: 295.40
Formula: C14H21N3O2S
CLOGP: 0.74
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 65.20
ALOGS: -3.37
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	N
50	mg	O
6	mg	P
25	mg	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	21.40 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	22 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.68 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	14 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.70 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	19 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.83 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 28, 1992	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product physical issue	4111.33	11.52	911	42648	3421	50558144
Product dose omission issue	1040.04	11.52	1016	42543	182822	50378743
Application site erythema	560.14	11.52	192	43367	4346	50557219
Migraine	494.45	11.52	453	43106	74827	50486738
Product quality issue	491.55	11.52	315	43244	30543	50531022
Application site burn	376.73	11.52	95	43464	681	50560884
Device deployment issue	332.86	11.52	122	43437	3374	50558191
Device malfunction	330.06	11.52	189	43370	14932	50546633
Application site pain	326.63	11.52	123	43436	3675	50557890
Application site discolouration	263.42	11.52	71	43488	679	50560886
Device issue	257.89	11.52	179	43380	19793	50541772
Application site paraesthesia	191.73	11.52	36	43523	39	50561526
Accidental exposure to product	143.83	11.52	135	43424	22922	50538643
Application site urticaria	136.77	11.52	34	43525	228	50561337
Application site rash	131.87	11.52	56	43503	2301	50559264
Application site irritation	123.42	11.52	48	43511	1567	50559998
Medication overuse headache	119.52	11.52	37	43522	598	50560967
Colitis ischaemic	117.73	11.52	83	43476	9400	50552165
Application site warmth	113.88	11.52	27	43532	144	50561421
Application site pruritus	109.79	11.52	57	43502	3702	50557863
Headache	99.53	11.52	760	42799	505775	50055790
Death	96.58	11.52	83	43476	325296	50236269
Needle issue	95.74	11.52	66	43493	7209	50554356
Arteriospasm coronary	94.83	11.52	50	43509	3352	50558213
Anxiety	89.10	11.52	345	43214	177261	50384304
Application site scar	81.84	11.52	22	43537	208	50561357
Injection site pain	78.66	11.52	242	43317	110782	50450783
Application site vesicles	78.49	11.52	33	43526	1322	50560243
Paraesthesia	76.89	11.52	253	43306	119990	50441575
Injection site haemorrhage	74.64	11.52	92	43467	21254	50540311
Application site swelling	73.04	11.52	24	43535	474	50561091
Glossodynia	71.41	11.52	8	43551	115561	50446004
Reversible cerebral vasoconstriction syndrome	70.24	11.52	35	43524	2084	50559481
Throat tightness	69.93	11.52	88	43471	20759	50540806
IIIrd nerve paresis	66.79	11.52	17	43542	127	50561438
Product substitution issue	66.77	11.52	71	43488	13986	50547579
Acute kidney injury	65.40	11.52	60	43499	227998	50333567
Device power source issue	65.12	11.52	22	43537	475	50561090
Wrong technique in product usage process	64.97	11.52	146	43413	55364	50506201
Systemic lupus erythematosus	63.37	11.52	21	43538	140601	50420964
Muscle twitching	63.02	11.52	72	43487	15359	50546206
Anaemia	61.69	11.52	76	43483	252380	50309185
Cerebral vasoconstriction	60.28	11.52	25	43534	967	50560598
Product leakage	59.80	11.52	21	43538	511	50561054
Application site exfoliation	58.72	11.52	18	43541	281	50561284
Coronary artery dissection	56.95	11.52	22	43537	705	50560860
Infusion related reaction	56.95	11.52	38	43521	169519	50392046
Arthropathy	54.93	11.52	34	43525	157872	50403693
Wound	54.82	11.52	12	43547	105782	50455783
Contraindicated product administered	54.75	11.52	30	43529	148928	50412637
Application site dryness	54.60	11.52	15	43544	155	50561410
Depression	53.32	11.52	282	43277	165141	50396424
Serotonin syndrome	52.69	11.52	84	43475	24629	50536936
Drug ineffective	51.96	11.52	990	42569	818343	49743222
Cholecystitis chronic	51.62	11.52	52	43507	9617	50551948
Application site reaction	51.39	11.52	20	43539	654	50560911
Product complaint	51.10	11.52	56	43503	11410	50550155
Treatment failure	50.18	11.52	28	43531	137609	50423956
Emotional distress	48.63	11.52	88	43471	28575	50532990
Dizziness	48.56	11.52	483	43076	345886	50215679
Abdominal discomfort	48.35	11.52	78	43481	231563	50330002
Application site scab	48.32	11.52	14	43545	178	50561387
Concussion	48.20	11.52	45	43514	7583	50553982
Device leakage	47.78	11.52	40	43519	5838	50555727
Post-traumatic neck syndrome	47.44	11.52	26	43533	1884	50559681
Somnambulism	47.42	11.52	37	43522	4887	50556678
Rheumatoid arthritis	47.36	11.52	63	43496	202487	50359078
Febrile neutropenia	46.86	11.52	13	43546	97654	50463911
Incorrect dose administered by device	46.84	11.52	32	43527	3443	50558122
Renal infarct	46.67	11.52	23	43536	1337	50560228
Pituitary tumour benign	46.33	11.52	25	43534	1756	50559809
Chest discomfort	45.51	11.52	179	43380	92543	50469022
Lower respiratory tract infection	45.07	11.52	13	43546	95188	50466377
Injection site bruising	44.47	11.52	98	43461	36670	50524895
Hostility	43.55	11.52	24	43535	1758	50559807
Cardiac failure	42.84	11.52	7	43552	76033	50485532
Libido increased	42.59	11.52	21	43538	1222	50560343
Neutropenia	42.30	11.52	39	43520	147926	50413639
Endometriosis	42.26	11.52	32	43527	4043	50557522
Soft tissue injury	41.90	11.52	22	43537	1462	50560103
Renal impairment	40.39	11.52	8	43551	75653	50485912
Application site inflammation	38.89	11.52	14	43545	367	50561198
Tension headache	38.85	11.52	26	43533	2705	50558860
Joint swelling	38.84	11.52	97	43462	245189	50316376
Disease progression	38.71	11.52	17	43542	95849	50465716
Expired product administered	38.41	11.52	34	43525	5348	50556217
Application site bruise	38.08	11.52	13	43546	290	50561275
Off label use	37.99	11.52	246	43313	474180	50087385
Nightmare	37.53	11.52	57	43502	16029	50545536
Atrial fibrillation	36.64	11.52	21	43538	101724	50459841
Pneumonia	36.30	11.52	185	43374	378216	50183349
Sternal fracture	35.76	11.52	22	43537	1980	50559585
Clonus	35.16	11.52	29	43530	4146	50557419
Hypotension	34.33	11.52	97	43462	235372	50326193
Suicidal ideation	33.99	11.52	115	43444	55270	50506295
Swelling	33.72	11.52	77	43482	200795	50360770
Alopecia	33.52	11.52	104	43455	244943	50316622
Nausea	33.49	11.52	818	42741	704580	49856985
Diarrhoea	33.37	11.52	335	43224	588141	49973424
Feeling abnormal	33.20	11.52	203	43356	125289	50436276
Angle closure glaucoma	32.93	11.52	21	43538	2013	50559552
Incorrect route of product administration	32.54	11.52	58	43501	18608	50542957
Drug specific antibody	32.46	11.52	20	43539	1805	50559760
Secondary adrenocortical insufficiency	32.43	11.52	17	43542	1126	50560439
Haemoglobin decreased	32.42	11.52	37	43522	127179	50434386
Muscle tightness	32.27	11.52	42	43517	10238	50551327
Hypoaesthesia	31.26	11.52	202	43357	127055	50434510
Therapeutic response unexpected	31.08	11.52	52	43507	15863	50545702
Infection	30.93	11.52	64	43495	172890	50388675
Pancytopenia	30.75	11.52	17	43542	84013	50477552
Transient global amnesia	30.59	11.52	12	43547	401	50561164
Dysgeusia	30.53	11.52	88	43471	38828	50522737
Pre-existing condition improved	30.48	11.52	34	43525	7063	50554502
Device defective	30.44	11.52	17	43542	1278	50560287
Chest pain	29.40	11.52	256	43303	176626	50384939
Hyponatraemia	29.09	11.52	24	43535	96115	50465450
Pharyngeal swelling	28.97	11.52	27	43532	4539	50557026
Peripheral swelling	28.44	11.52	87	43472	205849	50355716
Platelet count decreased	28.24	11.52	27	43532	100699	50460866
Hot flush	28.24	11.52	93	43466	44076	50517489
Application site discomfort	28.20	11.52	11	43548	362	50561203
Hyperkalaemia	28.06	11.52	4	43555	48085	50513480
Oxygen saturation decreased	28.01	11.52	14	43545	73234	50488331
Hepatic enzyme increased	27.95	11.52	47	43512	137333	50424232
Renal tubular acidosis	27.76	11.52	17	43542	1517	50560048
Interstitial lung disease	27.60	11.52	6	43553	53170	50508395
Sepsis	27.48	11.52	45	43514	132880	50428685
Application site erosion	27.38	11.52	9	43550	178	50561387
Migraine without aura	27.19	11.52	10	43549	279	50561286
Drug hypersensitivity	26.41	11.52	331	43228	250679	50310886
Malignant neoplasm progression	26.08	11.52	13	43546	68111	50493454
Vasospasm	25.62	11.52	12	43547	623	50560942
Hyperprolactinaemia	25.51	11.52	22	43537	3343	50558222
General physical health deterioration	25.21	11.52	53	43506	142381	50419184
Gastrointestinal haemorrhage	25.18	11.52	16	43543	73305	50488260
Underdose	24.46	11.52	54	43505	20224	50541341
Poor quality sleep	24.37	11.52	48	43511	16598	50544967
Cluster headache	24.37	11.52	11	43548	524	50561041
Blood creatinine increased	24.32	11.52	18	43541	76142	50485423
Pleural effusion	23.82	11.52	21	43538	81433	50480132
Injection site laceration	23.34	11.52	7	43552	101	50561464
Product use issue	22.95	11.52	60	43499	149415	50412150
Impaired healing	22.93	11.52	16	43543	69770	50491795
Synovitis	22.85	11.52	45	43514	123820	50437745
Injury	22.82	11.52	93	43466	48832	50512733
Personality disorder	22.62	11.52	23	43536	4301	50557264
Tremor	22.14	11.52	172	43387	114731	50446834
Cardiac failure congestive	22.08	11.52	24	43535	84358	50477207
Application site papules	22.02	11.52	6	43553	60	50561505
Vasoconstriction	21.95	11.52	10	43549	487	50561078
Photophobia	21.88	11.52	43	43516	14844	50546721
Multiple sclerosis	21.87	11.52	52	43507	20441	50541124
Septic shock	21.75	11.52	11	43548	57164	50504401
Rash	21.55	11.52	257	43302	437214	50124351
Palpitations	21.38	11.52	147	43412	94359	50467206
Paraesthesia oral	21.33	11.52	38	43521	12183	50549382
Stomatitis	21.23	11.52	34	43525	101310	50460255
Renal failure	21.20	11.52	37	43522	106596	50454969
Eyelid ptosis	20.56	11.52	26	43533	6161	50555404
Dependence	20.06	11.52	15	43544	1860	50559705
Neonatal respiratory distress	19.73	11.52	8	43551	292	50561273
Somnolence	19.67	11.52	212	43347	154773	50406792
Neck pain	19.53	11.52	99	43460	56968	50504597
Migraine with aura	19.51	11.52	16	43543	2269	50559296
Phonophobia	19.50	11.52	8	43551	301	50561264
Basilar migraine	19.23	11.52	5	43554	41	50561524
Irritability	19.21	11.52	61	43498	28365	50533200
Muscle spasms	18.95	11.52	178	43381	125375	50436190
Pyrexia	18.85	11.52	223	43336	379980	50181585
Narcolepsy	18.84	11.52	12	43547	1148	50560417
Sunburn	18.80	11.52	16	43543	2387	50559178
Product adhesion issue	18.79	11.52	21	43538	4371	50557194
Large intestinal ulcer haemorrhage	18.73	11.52	6	43553	109	50561456
Multiple organ dysfunction syndrome	18.68	11.52	10	43549	50327	50511238
Osteonecrosis of jaw	18.30	11.52	3	43556	32523	50529042
Spleen congestion	18.28	11.52	6	43553	118	50561447
Biliary dyskinesia	17.98	11.52	16	43543	2534	50559031
Cerebral venous thrombosis	17.89	11.52	14	43545	1857	50559708
Injection site injury	17.74	11.52	9	43550	557	50561008
Incorrect product administration duration	17.70	11.52	30	43529	9245	50552320
Decreased appetite	17.68	11.52	101	43458	200822	50360743
Thrombocytopenia	17.56	11.52	54	43505	127619	50433946
Middle insomnia	17.51	11.52	31	43528	9890	50551675
Post-traumatic stress disorder	17.43	11.52	20	43539	4283	50557282
Cough	17.32	11.52	129	43430	241135	50320430
Device use error	17.29	11.52	22	43537	5244	50556321
Blood testosterone increased	17.16	11.52	6	43553	144	50561421
Vision blurred	17.00	11.52	121	43438	78526	50483039
International normalised ratio increased	16.87	11.52	8	43551	43144	50518421
Lactic acidosis	16.83	11.52	4	43555	33351	50528214
Drug dependence	16.79	11.52	46	43513	19713	50541852
Hip arthroplasty	16.70	11.52	3	43556	30426	50531139
Subclavian artery thrombosis	16.46	11.52	6	43553	163	50561402
Drug effect less than expected	16.25	11.52	8	43551	464	50561101
Hyperacusis	16.18	11.52	13	43546	1791	50559774
Meningoradiculitis	16.14	11.52	5	43554	81	50561484
Application site dermatitis	16.13	11.52	6	43553	173	50561392
Sleep talking	15.99	11.52	10	43549	926	50560639
Memory impairment	15.95	11.52	120	43439	79240	50482325
Red blood cell sedimentation rate increased	15.93	11.52	3	43556	29413	50532152
Superior sagittal sinus thrombosis	15.85	11.52	9	43550	698	50560867
Bipolar disorder	15.84	11.52	24	43535	6733	50554832
Seizure	15.78	11.52	163	43396	117711	50443854
Neoplasm progression	15.73	11.52	3	43556	29154	50532411
Gastrooesophageal reflux disease	15.61	11.52	116	43443	76312	50485253
Major depression	15.50	11.52	24	43535	6860	50554705
Transverse sinus thrombosis	15.46	11.52	8	43551	516	50561049
Injury associated with device	15.26	11.52	16	43543	3101	50558464
Lichen planus	15.13	11.52	13	43546	1966	50559599
Cerebral venous sinus thrombosis	14.92	11.52	12	43547	1656	50559909
Hyperreflexia	14.67	11.52	20	43539	5098	50556467
Bone marrow failure	14.57	11.52	3	43556	27621	50533944
Hepatic function abnormal	14.50	11.52	5	43554	32676	50528889
Gastrointestinal disorder	14.42	11.52	38	43521	94418	50467147
Nipple pain	14.42	11.52	6	43553	234	50561331
Peripheral nerve injury	14.40	11.52	7	43552	395	50561170
Trismus	14.31	11.52	16	43543	3332	50558233
Burning sensation	14.28	11.52	77	43482	45369	50516196
Gallbladder disorder	14.25	11.52	39	43520	16703	50544862
Therapeutic response shortened	14.24	11.52	24	43535	7365	50554200
Ischaemic cerebral infarction	14.10	11.52	10	43549	1143	50560422
Pancreatic failure	14.05	11.52	9	43550	869	50560696
Potassium wasting nephropathy	14.02	11.52	4	43555	48	50561517
Melaena	14.00	11.52	3	43556	26861	50534704
Alanine aminotransferase increased	13.91	11.52	35	43524	88324	50473241
Rash maculo-papular	13.83	11.52	3	43556	26638	50534927
Multiple sclerosis relapse	13.64	11.52	73	43486	42891	50518674
Cardio-respiratory arrest	13.37	11.52	16	43543	53876	50507689
Pneumonia aspiration	13.32	11.52	5	43554	30999	50530566
Maternal exposure during pregnancy	13.16	11.52	82	43477	159696	50401869
Slow speech	13.15	11.52	10	43549	1272	50560293
Hyperhidrosis	13.10	11.52	126	43433	89300	50472265
Post viral fatigue syndrome	13.09	11.52	6	43553	296	50561269
Meningitis aseptic	13.09	11.52	17	43542	4135	50557430
Gallbladder injury	13.06	11.52	10	43549	1284	50560281
Cholestasis	12.91	11.52	3	43556	25398	50536167
Deep vein thrombosis	12.63	11.52	107	43452	73197	50488368
Sensory disturbance	12.60	11.52	30	43529	11799	50549766
Toxicity to various agents	12.38	11.52	120	43439	212379	50349186
Hepatotoxicity	12.37	11.52	4	43555	27222	50534343
Product packaging quantity issue	12.36	11.52	9	43550	1071	50560494
Blood HIV RNA increased	12.34	11.52	7	43552	542	50561023
Nasal discomfort	12.33	11.52	16	43543	3888	50557677
Influenza like illness	12.18	11.52	88	43471	57371	50504194
Chemical burn	12.08	11.52	6	43553	355	50561210
Knee arthroplasty	12.06	11.52	8	43551	35838	50525727
Respiratory disorder	11.86	11.52	6	43553	31181	50530384
Ovarian neoplasm	11.85	11.52	8	43551	844	50560721
Complement factor C4 decreased	11.85	11.52	5	43554	202	50561363
Premature delivery	11.63	11.52	3	43556	23660	50537905
Pharyngeal oedema	11.53	11.52	31	43528	13134	50548431

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product physical issue	992.79	18.11	199	6983	1889	29565456
Product dose omission issue	243.88	18.11	195	6987	96188	29471157
Migraine	128.65	18.11	62	7120	12368	29554977
Product quality issue	122.66	18.11	65	7117	15830	29551515
Device deployment issue	98.02	18.11	18	7164	100	29567245
Headache	79.29	18.11	147	7035	173860	29393485
Arteriospasm coronary	71.69	18.11	26	7156	2539	29564806
Device malfunction	63.36	18.11	34	7148	8473	29558872
Device issue	57.68	18.11	31	7151	7749	29559596
Serotonin syndrome	51.76	18.11	39	7143	17473	29549872
Throat tightness	49.08	18.11	27	7155	7064	29560281
IIIrd nerve paresis	44.63	18.11	9	7173	87	29567258
Accidental exposure to product	41.08	18.11	28	7154	10725	29556620
Hyperhidrosis	37.71	18.11	61	7121	64479	29502866
Injection site pain	36.25	18.11	42	7140	32404	29534941
Cluster headache	34.52	18.11	10	7172	476	29566869
Application site pain	32.43	18.11	13	7169	1666	29565679
Medication overuse headache	31.18	18.11	7	7175	117	29567228
Myofascial pain syndrome	29.41	18.11	8	7174	302	29567043
Acute kidney injury	29.23	18.11	14	7168	265253	29302092
Needle issue	27.46	18.11	16	7166	4667	29562678
Application site burn	27.44	18.11	7	7175	205	29567140
Xanthelasma	27.03	18.11	6	7176	95	29567250
Gastrointestinal tract irritation	26.82	18.11	7	7175	225	29567120
Anophthalmos	26.52	18.11	4	7178	4	29567341
Congenital genital malformation male	24.90	18.11	4	7178	8	29567337
Facial pain	24.90	18.11	11	7171	1794	29565551
Foetal malnutrition	23.96	18.11	5	7177	58	29567287
Burns second degree	23.77	18.11	7	7175	353	29566992
Autonomic dysreflexia	23.16	18.11	5	7177	69	29567276
Death	21.71	18.11	31	7151	342053	29225292
Drug ineffective	21.49	18.11	156	7026	363014	29204331
Capillaritis	21.28	18.11	5	7177	103	29567242
Foetal exposure during pregnancy	21.12	18.11	33	7149	33834	29533511
Muscle tightness	20.73	18.11	13	7169	4325	29563020
Electrocardiogram ST segment elevation	20.32	18.11	13	7169	4479	29562866
Craniosynostosis	20.29	18.11	6	7176	307	29567038
Application site erythema	20.28	18.11	10	7172	2089	29565256
Irritable bowel syndrome	19.94	18.11	11	7171	2890	29564455
Injection site haemorrhage	19.03	18.11	16	7166	8370	29558975
Paraesthesia	18.99	18.11	41	7141	53804	29513541
Tobacco abuse	18.93	18.11	6	7176	388	29566957
Anxiety	18.51	18.11	54	7128	85311	29482034
Aphasia	18.39	18.11	23	7159	19175	29548170
Insomnia	18.15	18.11	55	7127	88706	29478639

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product physical issue	1348.01	12.34	329	37679	3120	64457604
Migraine	527.96	12.34	373	37635	62304	64398420
Application site erythema	404.71	12.34	138	37870	4551	64456173
Product dose omission issue	321.94	12.34	479	37529	194268	64266456
Application site burn	285.93	12.34	71	37937	725	64459999
Application site pain	238.59	12.34	91	37917	4157	64456567
Product quality issue	227	12.34	167	37841	29632	64431092
Application site discolouration	193.71	12.34	51	37957	669	64460055
Device malfunction	186.59	12.34	121	37887	17512	64443212
Application site paraesthesia	181.44	12.34	32	37976	37	64460687
Headache	159.65	12.34	675	37333	528792	63931932
Arteriospasm coronary	151.90	12.34	71	37937	5394	64455330
Accidental exposure to product	147.18	12.34	123	37885	26241	64434483
Medication overuse headache	124.81	12.34	36	37972	674	64460050
IIIrd nerve paresis	117.60	12.34	26	37982	151	64460573
Throat tightness	116.91	12.34	102	37906	23058	64437666
Acute kidney injury	114.74	12.34	61	37947	449179	64011545
Colitis ischaemic	110.83	12.34	79	37929	13335	64447389
Anxiety	103.71	12.34	308	37700	202341	64258383
Application site pruritus	101.52	12.34	47	37961	3492	64457232
Application site irritation	100.29	12.34	37	37971	1539	64459185
Application site warmth	100.21	12.34	23	37985	162	64460562
Device deployment issue	98.49	12.34	43	37965	2783	64457941
Paraesthesia	93.50	12.34	229	37779	134293	64326431
Death	92.54	12.34	89	37919	482616	63978108
Application site rash	89.10	12.34	36	37972	1918	64458806
Application site urticaria	89	12.34	22	37986	220	64460504
Reversible cerebral vasoconstriction syndrome	86.08	12.34	37	37971	2305	64458419
Device issue	80.28	12.34	82	37926	22566	64438158
Serotonin syndrome	80.05	12.34	107	37901	39175	64421549
Wrong technique in product usage process	79.94	12.34	140	37868	64834	64395890
Anaemia	77.08	12.34	66	37942	378614	64082110
Application site swelling	71.86	12.34	23	37985	619	64460105
Application site scar	68.24	12.34	17	37991	176	64460548
Cerebral vasoconstriction	67.98	12.34	26	37982	1196	64459528
Muscle twitching	64.11	12.34	67	37941	18931	64441793
Dizziness	62.27	12.34	450	37558	429713	64031011
Depression	60.66	12.34	241	37767	183050	64277674
Endometriosis	58.76	12.34	30	37978	2762	64457962
Emotional distress	58.40	12.34	88	37920	35950	64424774
Cardiac failure	56.68	12.34	6	38002	132367	64328357
Chest discomfort	56.05	12.34	173	37835	115933	64344791
Application site vesicles	55.65	12.34	23	37985	1299	64459425
Febrile neutropenia	54.80	12.34	21	37987	187636	64273088
Injection site pain	54.71	12.34	167	37841	111241	64349483
Post-traumatic neck syndrome	53.75	12.34	25	37983	1877	64458847
Coronary artery dissection	52.92	12.34	20	37988	890	64459834
Pneumonia	52.27	12.34	163	37845	559413	63901311
Pituitary tumour benign	52.24	12.34	26	37982	2267	64458457
Cholecystitis chronic	51.13	12.34	43	37965	9244	64451480
Nausea	48.54	12.34	689	37319	785111	63675613
Soft tissue injury	48.53	12.34	22	37986	1557	64459167
Muscle tightness	48.29	12.34	45	37963	11070	64449654
Drug ineffective	48.09	12.34	727	37281	839520	63621204
Injection site haemorrhage	47.73	12.34	65	37943	24213	64436511
Chest pain	47.11	12.34	268	37740	235712	64225012
Sepsis	46.98	12.34	40	37968	230301	64230423
Cluster headache	46.92	12.34	18	37990	835	64459889
Hypoaesthesia	46.88	12.34	184	37824	138924	64321800
Concussion	46.29	12.34	38	37970	7900	64452824
Hot flush	46.04	12.34	91	37917	46144	64414580
Application site exfoliation	46.03	12.34	14	37994	317	64460407
Neutropenia	46.03	12.34	44	37964	239580	64221144
Tension headache	45.36	12.34	27	37981	3356	64457368
Renal infarct	45.27	12.34	24	37984	2387	64458337
Renal impairment	44.92	12.34	12	37996	135005	64325719
Application site dryness	44.59	12.34	12	37996	172	64460552
Hostility	44.38	12.34	23	37985	2184	64458540
Renal failure	44.35	12.34	26	37982	181662	64279062
Incorrect route of product administration	43.73	12.34	61	37947	23237	64437487
Libido increased	42.87	12.34	21	37987	1769	64458955
Product substitution issue	41.62	12.34	52	37956	17809	64442915
Sternal fracture	41.16	12.34	22	37986	2225	64458499
Disease progression	41.12	12.34	16	37992	141664	64319060
Device power source issue	40.99	12.34	16	37992	778	64459946
Hyperkalaemia	39.86	12.34	6	38002	101123	64359601
Hypotension	38.39	12.34	107	37901	380867	64079857
Interstitial lung disease	38.06	12.34	6	38002	97726	64362998
Pancytopenia	37.16	12.34	19	37989	143290	64317434
Atrial fibrillation	37.02	12.34	28	37980	171061	64289663
Drug specific antibody	36.94	12.34	20	37988	2075	64458649
Platelet count decreased	36.86	12.34	27	37981	167684	64293040
Infusion related reaction	36.77	12.34	26	37982	164441	64296283
Injection site bruising	35.50	12.34	71	37937	36302	64424422
Injury	35.38	12.34	92	37916	55900	64404824
Clonus	35.29	12.34	29	37979	6038	64454686
Hyponatraemia	35.12	12.34	22	37986	148317	64312407
Angle closure glaucoma	35.09	12.34	21	37987	2636	64458088
Drug hypersensitivity	35.00	12.34	250	37758	237565	64223159
Feeling abnormal	34.44	12.34	163	37845	133439	64327285
Multiple organ dysfunction syndrome	33.76	12.34	9	37999	101404	64359320
Application site inflammation	33.66	12.34	12	37996	452	64460272
Thrombocytopenia	33.48	12.34	50	37958	223751	64236973
Septic shock	32.12	12.34	11	37997	105426	64355298
Suicidal ideation	31.95	12.34	99	37909	66443	64394281
Pain	31.16	12.34	478	37530	553033	63907691
Pharyngeal swelling	31.14	12.34	26	37982	5533	64455191
Palpitations	31.07	12.34	133	37875	104355	64356369
Photophobia	30.57	12.34	44	37964	17249	64443475
Vision blurred	30.03	12.34	119	37889	90197	64370527
Application site scab	29.75	12.34	9	37999	200	64460524
Haemoglobin decreased	29.74	12.34	43	37965	195020	64265704
Treatment failure	29.53	12.34	16	37992	116800	64343924
Nightmare	29.47	12.34	48	37960	20945	64439779
Expired product administered	29.47	12.34	26	37982	5961	64454763
Gastrointestinal haemorrhage	29.46	12.34	21	37987	132291	64328433
Transient global amnesia	29.06	12.34	12	37996	676	64460048
Blood creatinine increased	28.38	12.34	23	37985	135759	64324965
Pleural effusion	28.30	12.34	20	37988	126539	64334185
Application site bruise	28.20	12.34	9	37999	240	64460484
Subclavian artery thrombosis	27.89	12.34	6	38002	30	64460694
Malignant neoplasm progression	27.75	12.34	16	37992	112855	64347869
Secondary adrenocortical insufficiency	27.05	12.34	17	37991	2328	64458396
Hyperprolactinaemia	26.99	12.34	21	37987	4044	64456680
Off label use	26.49	12.34	242	37766	632564	63828160
Pyrexia	26.36	12.34	207	37801	558437	63902287
Personality disorder	26.32	12.34	22	37986	4689	64456035
Product adhesion issue	26.31	12.34	17	37991	2442	64458282
Product leakage	26.19	12.34	11	37997	647	64460077
Device leakage	25.85	12.34	28	37980	8238	64452486
Vasospasm	25.49	12.34	12	37996	926	64459798
Therapeutic response unexpected	25.41	12.34	40	37968	16961	64443763
Lower respiratory tract infection	25.35	12.34	12	37996	94602	64366122
Application site reaction	25.31	12.34	11	37997	704	64460020
Application site discomfort	25.19	12.34	9	37999	341	64460383
Cardiac failure congestive	25.02	12.34	24	37984	130556	64330168
Hyperhidrosis	24.97	12.34	142	37866	124778	64335946
Incorrect dose administered by device	24.71	12.34	20	37988	4077	64456647
Somnambulism	24.65	12.34	22	37986	5119	64455605
Migraine without aura	24.56	12.34	8	38000	228	64460496
Temperature intolerance	24.15	12.34	27	37981	8228	64452496
Respiratory failure	24.10	12.34	36	37972	161147	64299577
Insomnia	24.08	12.34	199	37809	197637	64263087
Cerebral venous thrombosis	23.99	12.34	16	37992	2425	64458299
Muscle spasms	23.55	12.34	153	37855	140870	64319854
Dysgeusia	23.52	12.34	71	37937	46976	64413748
Poor quality sleep	23.50	12.34	41	37967	18910	64441814
Electrocardiogram ST segment elevation	23.42	12.34	25	37983	7234	64453490
Drug dependence	23.41	12.34	57	37951	33255	64427469
Renal tubular acidosis	23.36	12.34	17	37991	2962	64457762
Vasoconstriction	23.34	12.34	10	37998	618	64460106
Memory impairment	23.15	12.34	106	37902	85576	64375148
Glossodynia	22.98	12.34	5	38003	64691	64396033
Paraesthesia oral	22.61	12.34	33	37975	13098	64447626
Infection	22.48	12.34	47	37961	184833	64275891
Phonophobia	22.42	12.34	9	37999	471	64460253
Neck pain	22.02	12.34	83	37925	61450	64399274
Wound	21.59	12.34	9	37999	76468	64384256
Gallbladder disorder	21.32	12.34	37	37971	16993	64443731
Head discomfort	20.75	12.34	30	37978	11804	64448920
Myofascial pain syndrome	20.65	12.34	13	37995	1785	64458939
Product complaint	20.52	12.34	30	37978	11924	64448800
Therapeutic product effect incomplete	20.26	12.34	117	37891	103365	64357359
Middle insomnia	20.23	12.34	31	37977	12846	64447878
Tremor	20.17	12.34	153	37855	148077	64312647
Migraine with aura	19.98	12.34	14	37994	2298	64458426
Pharyngeal oedema	19.78	12.34	34	37974	15497	64445227
International normalised ratio increased	19.78	12.34	11	37997	79156	64381568
Application site papules	19.71	12.34	5	38003	56	64460668
Diarrhoea	19.59	12.34	304	37704	722400	63738324
Burns second degree	19.49	12.34	10	37998	930	64459794
Basilar migraine	19.47	12.34	5	38003	59	64460665
Burning sensation	19.47	12.34	69	37939	49595	64411129
Decreased appetite	19.08	12.34	93	37915	281196	64179528
Oxygen saturation decreased	19.06	12.34	21	37987	107155	64353569
Meningitis aseptic	18.96	12.34	20	37988	5710	64455014
Irritability	18.88	12.34	56	37952	36690	64424034
Flushing	18.85	12.34	94	37914	78554	64382170
Epistaxis	18.84	12.34	18	37990	98113	64362611
Xanthelasma	18.80	12.34	6	38002	160	64460564
Hyperreflexia	18.58	12.34	22	37986	7126	64453598
Dependence	18.51	12.34	13	37995	2142	64458582
Facial pain	18.41	12.34	23	37985	7872	64452852
Drug effect less than expected	18.30	12.34	8	38000	519	64460205
Pre-existing condition improved	18.26	12.34	18	37990	4744	64455980
Post-traumatic stress disorder	18.22	12.34	17	37991	4188	64456536
Aphasia	17.93	12.34	59	37949	40847	64419877
Peripheral coldness	17.65	12.34	30	37978	13554	64447170
Blood bilirubin increased	17.53	12.34	6	38002	57547	64403177
Ovarian neoplasm	17.53	12.34	8	38000	575	64460149
Biliary dyskinesia	17.39	12.34	13	37995	2359	64458365
Loss of consciousness	17.38	12.34	148	37860	148217	64312507
Visual impairment	17.37	12.34	88	37920	73989	64386735
Hyperacusis	17.33	12.34	12	37996	1933	64458791
Transverse sinus thrombosis	17.06	12.34	8	38000	612	64460112
Application site erosion	17.01	12.34	6	38002	219	64460505
Gastrooesophageal reflux disease	16.93	12.34	95	37913	83048	64377676
Burns third degree	16.82	12.34	7	38001	402	64460322
Bone marrow failure	16.45	12.34	4	38004	47948	64412776
Superior sagittal sinus thrombosis	16.33	12.34	9	37999	967	64459757
Withdrawal syndrome	16.30	12.34	40	37968	23452	64437272
Lactic acidosis	16.12	12.34	8	38000	61402	64399322
Injection site laceration	16.08	12.34	5	38003	122	64460602
Multiple sclerosis relapse	15.99	12.34	57	37951	41078	64419646
Rheumatoid arthritis	15.88	12.34	47	37961	164247	64296477
Injection site erythema	15.83	12.34	83	37925	70717	64390007
Aspartate aminotransferase increased	15.81	12.34	29	37979	119759	64340965
Haematuria	15.69	12.34	8	38000	60463	64400261
Hypoglycaemia	15.56	12.34	18	37990	89874	64370850
Meningoradiculitis	15.50	12.34	5	38003	138	64460586
Cerebral venous sinus thrombosis	15.49	12.34	11	37997	1844	64458880
Sunburn	15.47	12.34	14	37994	3318	64457406
Large intestinal ulcer haemorrhage	15.40	12.34	6	38002	290	64460434
General physical health deterioration	15.40	12.34	65	37943	204360	64256364
Pancreatic failure	15.39	12.34	10	37998	1450	64459274
Blood pressure systolic increased	15.34	12.34	5	38003	49448	64411276
Post viral fatigue syndrome	15.25	12.34	6	38002	298	64460426
Systemic lupus erythematosus	15.18	12.34	14	37994	77598	64383126
Toxicity to various agents	15.17	12.34	139	37869	363374	64097350
Deep vein thrombosis	15.11	12.34	110	37898	105072	64355652
Gallbladder injury	14.97	12.34	9	37999	1139	64459585
Neoplasm progression	14.89	12.34	3	38005	40961	64419763
Gastrointestinal tract irritation	14.88	12.34	7	38001	539	64460185
Incorrect disposal of product	14.73	12.34	8	38000	835	64459889
Torsade de pointes	14.73	12.34	32	37976	17331	64443393
Cardio-respiratory arrest	14.68	12.34	22	37986	98371	64362353
Incorrect product administration duration	14.64	12.34	23	37985	9735	64450989
Device difficult to use	14.57	12.34	23	37985	9775	64450949
Vertigo	14.47	12.34	71	37937	58940	64401784
Impaired healing	14.26	12.34	9	37999	60464	64400260
Needle issue	14.11	12.34	22	37986	9250	64451474
Pericardial effusion	14.01	12.34	3	38005	39251	64421473
Major depression	13.98	12.34	20	37988	7796	64452928
Therapeutic response shortened	13.93	12.34	23	37985	10147	64450577
Hormone level abnormal	13.92	12.34	10	37998	1707	64459017
Peripheral nerve injury	13.87	12.34	7	38001	629	64460095
Eyelid ptosis	13.67	12.34	22	37986	9503	64451221
Injection site urticaria	13.62	12.34	24	37984	11157	64449567
Haemorrhage	13.61	12.34	16	37992	79335	64381389
Bradycardia	13.58	12.34	31	37977	118188	64342536
Contraindicated product administered	13.45	12.34	27	37981	107802	64352922
Nasal oedema	13.40	12.34	8	38000	1000	64459724
Eye pain	13.32	12.34	45	37963	31580	64429144
Alanine aminotransferase increased	13.27	12.34	40	37968	138991	64321733
Lichen planus	13.27	12.34	11	37997	2317	64458407
Product dispensing error	13.21	12.34	24	37984	11426	64449298
Complement factor C4 decreased	13.01	12.34	5	38003	233	64460491
Cytomegalovirus infection	12.96	12.34	3	38005	37196	64423528
Underdose	12.92	12.34	39	37969	25790	64434934
Choking sensation	12.89	12.34	13	37995	3522	64457202
Arthropathy	12.89	12.34	33	37975	120934	64339790
Capillaritis	12.89	12.34	5	38003	239	64460485
Panic attack	12.79	12.34	34	37974	20919	64439805
Neutrophil count decreased	12.78	12.34	16	37992	77180	64383544
Body temperature increased	12.74	12.34	49	37959	36617	64424107
Trismus	12.60	12.34	15	37993	4886	64455838
Seizure	12.56	12.34	152	37856	166740	64293984
Hepatotoxicity	12.46	12.34	4	38004	39958	64420766
Slow speech	12.40	12.34	10	37998	2027	64458697

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N02CC01	NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Selective serotonin (5HT1) agonists
CHEBI has role	CHEBI:35941	serotonin agonists
FDA MoA	N0000175763	Serotonin 1b Receptor Agonists
FDA MoA	N0000175764	Serotonin 1d Receptor Agonists
FDA EPC	N0000175765	Serotonin-1b and Serotonin-1d Receptor Agonist
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D058825	Serotonin 5-HT1 Receptor Agonists
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017366	Serotonin Receptor Agonists
MeSH PA	D014662	Vasoconstrictor Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Migraine	indication	37796009	DOID:6364
Cluster headache syndrome	indication	193031009
Tachyarrhythmia	contraindication	6285003
Alcoholism	contraindication	7200002
Hypercholesterolemia	contraindication	13644009
Myocardial infarction	contraindication	22298006	DOID:5844
Hypertensive disorder	contraindication	38341003	DOID:10763
Gastrointestinal ulcer	contraindication	40845000
Body fluid retention	contraindication	43498006
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Hemiplegic migraine	contraindication	59292006
Hepatic failure	contraindication	59927004
Blood coagulation disorder	contraindication	64779008	DOID:1247
Diabetes mellitus	contraindication	73211009	DOID:9351
Gastrointestinal hemorrhage	contraindication	74474003
Vascular insufficiency of intestine	contraindication	82196007
Epilepsy	contraindication	84757009	DOID:1826
Prinzmetal angina	contraindication	87343002
Kidney disease	contraindication	90708001	DOID:557
Liver function tests abnormal	contraindication	166603001
Angina pectoris	contraindication	194828000
Cerebrovascular accident	contraindication	230690007
Coronary artery bypass graft	contraindication	232717009
Disease of liver	contraindication	235856003	DOID:409
Transient ischemic attack	contraindication	266257000	DOID:224
Esophageal dysmotility	contraindication	266434009	DOID:9192
Edema	contraindication	267038008
Anemia	contraindication	271737000	DOID:2355
Cerebral ischemia	contraindication	287731003
Pregnancy, function	contraindication	289908002
Thromboembolic disorder	contraindication	371039008
Serotonin syndrome	contraindication	371089000
Cardiovascular event risk	contraindication	395112001
Peripheral vascular disease	contraindication	400047006
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Hypertensive urgency	contraindication	443482000
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.23	acidic
pKa2	13.42	acidic
pKa3	8.28	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	8327844	Oct. 3, 2023	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	7975690	Aug. 18, 2025	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	8590530	Sept. 15, 2025	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
500MG;EQ 85MG BASE	TREXIMET	CURRAX	N021926	April 15, 2008	RX	TABLET	ORAL	7332183	Oct. 2, 2025	TREATMENT OF MIGRAINE
60MG;EQ 10MG BASE	TREXIMET	CURRAX	N021926	May 14, 2015	DISCN	TABLET	ORAL	7332183	Oct. 2, 2025	ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY	TOSYMRA	UPSHER SMITH LABS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	8440631	May 9, 2026	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10124132	March 6, 2027	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10124132	March 6, 2027	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10124132	March 6, 2027	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	7973058	April 12, 2027	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	8155737	April 12, 2027	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	8470853	April 12, 2027	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	9427578	April 12, 2027	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	ALSUMA	MERIDIAN MEDCL	N022377	June 29, 2010	DISCN	INJECTABLE	SUBCUTANEOUS	7811254	Aug. 26, 2027	ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	8875704	April 7, 2028	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	8366600	April 21, 2029	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10076615	July 30, 2029	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10076615	July 30, 2029	METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10076615	July 30, 2029	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
10MG/SPRAY	TOSYMRA	UPSHER SMITH LABS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	10603305	June 16, 2030	ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY	TOSYMRA	UPSHER SMITH LABS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	11337962	June 16, 2030	ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY	TOSYMRA	UPSHER SMITH LABS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	9610280	June 16, 2030	ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY	TOSYMRA	UPSHER SMITH LABS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	9974770	June 16, 2030	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	9649456	Oct. 21, 2030	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	9649456	Oct. 21, 2030	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	9649456	Oct. 21, 2030	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	8983594	Nov. 19, 2030	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
10MG/SPRAY	TOSYMRA	UPSHER SMITH LABS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	9211282	July 19, 2031	ACUTE TREATMENT OF MIGRAINE
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	9327114	Oct. 8, 2032	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10478574	Nov. 4, 2033	METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	ZEMBRACE SYMTOUCH	UPSHER SMITH LABS	N208223	Jan. 28, 2016	RX	SOLUTION	SUBCUTANEOUS	10537554	Jan. 29, 2036	TREATMENT OF MIGRAINE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN	AGONIST	Ki	8.92	CHEMBL	CHEMBL
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN	AGONIST	Ki	8.26	CHEMBL	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		IC50	8.14	CHEMBL
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN	ANTAGONIST	Ki	5.60	IUPHAR
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN	ANTAGONIST	Ki	6	IUPHAR
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN		IC50	8.03	CHEMBL
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		IC50	6.30	CHEMBL
5-hydroxytryptamine receptor 1F	GPCR	P30939	5HT1F_HUMAN		Ki	7.59	CHEMBL
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN		IC50	5.26	CHEMBL
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	5.17	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.64	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.42	CHEMBL
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	7.64	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	6.19	CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT	ANTAGONIST	Ki	6.60	IUPHAR
5-hydroxytryptamine receptor 1D	GPCR		5HT1D_PIG		IC50	7.70	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_MOUSE		IC50	6.35	CHEMBL
5-hydroxytryptamine receptor 1D	GPCR		5HT1D_RAT		IC50	7.21	CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	ANTAGONIST	Ki	5.20	IUPHAR
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_GORGO		Ki	8.19	CHEMBL
5-hydroxytryptamine 1D receptor	Unclassified		Q8MI13_BOVIN		IC50	7.23	CHEMBL
5-hydroxytryptamine receptor 5A	GPCR		5HT5A_MOUSE	AGONIST	Ki	4.80	IUPHAR

External reference:

ID	Source
4021050	VUID
N0000148514	NUI
D00451	KEGG_DRUG
103628-48-4	SECONDARY_CAS_RN
4020790	VANDF
4021050	VANDF
C0075632	UMLSCUI
CHEBI:10650	CHEBI
CHEMBL128	ChEMBL_ID
DB00669	DRUGBANK_ID
CHEMBL1201150	ChEMBL_ID
D018170	MESH_DESCRIPTOR_UI
5358	PUBCHEM_CID
54	IUPHAR_LIGAND_ID
6125	INN_ID
8R78F6L9VO	UNII
37418	RXNORM
158892	MMSL
166806	MMSL
25268	MMSL
31925	MMSL
5536	MMSL
d03160	MMSL
004044	NDDF
004045	NDDF
322822007	SNOMEDCT_US
395892000	SNOMEDCT_US
96215002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Sumatriptan	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2013	INJECTION	4 mg	SUBCUTANEOUS	ANDA	28 sections
Sumatriptan	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2014	INJECTION	6 mg	SUBCUTANEOUS	ANDA	28 sections
SUMATRIPTAN	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9638	INJECTION	6 mg	SUBCUTANEOUS	ANDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0478	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0479	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0523	SPRAY	20 mg	NASAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0524	SPRAY	5 mg	NASAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0735	TABLET, FILM COATED	25 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0736	TABLET, FILM COATED	50 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0737	TABLET, FILM COATED	100 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0739	INJECTION	4 mg	SUBCUTANEOUS	NDA	28 sections
ZEMBRACE SYMTOUCH	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0809	INJECTION, SOLUTION	3 mg	SUBCUTANEOUS	NDA	31 sections
TOSYMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0812	SPRAY	10 mg	NASAL	NDA	31 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5630	TABLET, FILM COATED	25 mg	ORAL	ANDA	28 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5631	TABLET, FILM COATED	50 mg	ORAL	ANDA	28 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5632	TABLET, FILM COATED	100 mg	ORAL	ANDA	28 sections
Sumatriptan	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1818	SPRAY	5 mg	NASAL	ANDA	28 sections
Sumatriptan	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1859	SPRAY	20 mg	NASAL	ANDA	28 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	16590-300	TABLET, FILM COATED	100 mg	ORAL	NDA	13 sections
SUMATRIPTAN SUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-408	TABLET	50 mg	ORAL	ANDA	27 sections
SUMATRIPTAN SUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-950	TABLET	25 mg	ORAL	ANDA	27 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	16714-040	INJECTION	6 mg	SUBCUTANEOUS	ANDA	27 sections
Sumatriptan	Human Prescription Drug Label	1	16714-796	TABLET	25 mg	ORAL	ANDA	27 sections
Sumatriptan	Human Prescription Drug Label	1	16714-797	TABLET	50 mg	ORAL	ANDA	27 sections
Sumatriptan	Human Prescription Drug Label	1	16714-798	TABLET	100 mg	ORAL	ANDA	27 sections
Sumatriptan and Naproxen Sodium	Human Prescription Drug Label	2	16714-891	TABLET, FILM COATED	85 mg	ORAL	ANDA	32 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	21695-154	TABLET, FILM COATED	50 mg	ORAL	NDA	26 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-872	TABLET	25 mg	ORAL	ANDA	27 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-873	TABLET	50 mg	ORAL	ANDA	27 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-874	TABLET	100 mg	ORAL	ANDA	27 sections